Sun Pharmaceutical Industries Ltd
Quarterly Financial Results for Q1 of FY 2026-27
RESULTS
▲ Positive Development
LOW RISK
📅 Filed on BSE: 31 Jul 2026, 02:28 PM IST · BSE ID: 1b75199a-54e0-4232-bea3-222d957de3f7
View Original BSE Filing (PDF)
💡
In Simple Terms
Sun Pharma announced its first-quarter financial results, reporting a profit of ₹11,151.4 Million.
🤖 AI Summary
- Board approved Unaudited Standalone and Consolidated Financial Results for Q1 of FY 2026-27.
- Profit for the period (Standalone) was ₹11,151.4 Million for Q1 FY27.
- Total revenue from operations (Standalone) reached ₹57,411.3 Million for Q1 FY27.
- Company recognized an incremental cost of ₹315.3 Million in Q1 FY27 for employee compensation under New Labour Codes.
- Sun Pharma opted for concessional tax regime under Section 115BAA effective from FY 2026-27.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Total revenue from operations (Standalone)
57,411.3 Million
2.62%
Profit for the period (Standalone)
11,151.4 Million
49.67%
Exceptional items cost (Q1 FY27)
315.3 Million
Total other comprehensive income (Standalone)
1,443.3 Million
633.48%
🏢 How This Affects the Company
The adoption of the concessional tax regime under Section 115BAA will reduce the corporate tax rate to an effective 25.168% from 34.944%, impacting future tax expenses. The company reported a Profit for the period of ₹11,151.4 Million for Q1 FY27.
The reassessment of employee compensation structures under New Labour Codes resulted in an incremental cost of ₹315.3 Million for Q1 FY27, indicating adjustments to workforce-related expenses.
👥 What This Means For Shareholders
✅
Action Required
No action is required from shareholders based on this financial results filing.
👤
Who Is Affected
All shareholders are affected by the company's financial performance, with the reported standalone Profit for the period at ₹11,151.4 Million for Q1 FY27. Earnings per share (Basic and Diluted) were ₹4.6 for Q1 FY27.
🔍
Management Signal
Management's decision to adopt the concessional tax regime under Section 115BAA indicates a strategic move to optimize tax liabilities for current and future fiscal years.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Review Q2 FY27 financial results for sustained revenue and profit growth.
Monitor future filings for details on New Labour Codes impact on employee costs.
Observe any press releases or investor calls for insights on tax regime impact.
LOW RISK
The filing indicates positive financial performance and a move to a favorable tax regime.
💡 Investor Takeaway
Sun Pharmaceutical Industries reported a standalone profit of ₹11,151.4 Million for Q1 FY27, up from ₹7,450.6 Million in Q1 FY26. Total revenue from operations stood at ₹57,411.3 Million. The company also confirmed its shift to a concessional tax regime from FY 2026-27.
⚖️ Strengths & Concerns
✅ Positives
- Profit for the period (Standalone) increased to ₹11,151.4 Million in Q1 FY27 from ₹7,450.6 Million in Q1 FY26.
- Total revenue from operations (Standalone) increased to ₹57,411.3 Million in Q1 FY27 from ₹55,948.8 Million in Q1 FY26.
⚠️ Concerns
- Exceptional items included a cost of ₹315.3 Million in Q1 FY27 related to reassessment of employee compensation structures.
- Research and development expenses incurred decreased to ₹4,635.9 Million in Q1 FY27 from ₹6,146.9 Million in Q1 FY26.
❓ Frequently Asked Questions
What was Sun Pharmaceutical Industries' standalone profit for Q1 FY27?
Sun Pharmaceutical Industries reported a standalone profit for the period of ₹11,151.4 Million for the quarter ended June 30, 2026.
What was the total revenue from operations for Sun Pharma in Q1 FY27?
The total revenue from operations (standalone) for Sun Pharmaceutical Industries was ₹57,411.3 Million for Q1 FY27, compared to ₹55,948.8 Million in Q1 FY26.
What was the Basic Earnings Per Share (EPS) for Sun Pharma in Q1 FY27?
The Basic Earnings Per Share (EPS) for Sun Pharmaceutical Industries was ₹4.6 for the quarter ended June 30, 2026, up from ₹3.1 in Q1 FY26.
Did Sun Pharma report any exceptional items in Q1 FY27?
Yes, Sun Pharmaceutical Industries reported exceptional items totaling ₹315.3 Million for Q1 FY27, primarily due to reassessment of employee compensation structures.
What tax regime change did Sun Pharma announce for FY 2026-27?
Sun Pharmaceutical Industries decided to exercise the option under Section 115BAA of the Income-tax Act, 1961, for a concessional tax regime at an effective rate of 25.168% from FY 2026-27.
Questions based on this BSE filing only. For information purposes.